EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Ralf Stemkens iD, Arthur Lemson, Simon E Koele iD, Elin M Svensson, Lindsey H M Te Brake, Reinout van Crevel iD, Martin J Boeree, Wouter Hoefsloot, Jakko van Ingen iD, Rob E Aarnoutse

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae309 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Ralf Stemkens und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Clofazimine, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Clofazimine is a promising drug for the treatment of nontuberculous mycobacterial (NTM) diseases. Accumulation of clofazimine to reach steady-state plasma concentrations takes months. A loading dose may reduce the time to steady-state-like concentrations. We evaluated the pharmacokinetics (PK), safety and tolerability of a loading dose regimen in patients with NTM disease.

Methods

Adult participants received a 4-week loading dose regimen of 300 mg clofazimine once daily, followed by a maintenance dose of 100 mg once daily (combined with other antimycobacterial drugs). Blood samples for PK analysis were collected on three occasions. A population PK model for clofazimine was developed and simulations were performed to assess the time to reach steady-state-like (target) concentrations for different dosing regimens.

Results

Twelve participants were included. The geometric mean peak and trough clofazimine concentrations after the 4-week loading phase were 0.87 and 0.50 mg/L, respectively. Adverse events were common, but mostly mild and none led to discontinuation of clofazimine. Our loading dose regimen reduced the predicted median time to target concentrations by 1.5 months compared to no loading dose (3.8 versus 5.3 months). Further time benefit was predicted with a 6-week loading dose regimen (1.4 versus 5.3 months).

Conclusion

A 4-week loading dose regimen of 300 mg once daily reduced the time to target clofazimine concentrations and was safe and well-tolerated. Extending the loading phase to 6 weeks could further decrease the time to target concentrations. Using a loading dose of clofazimine is a feasible strategy to optimize treatment of NTM disease. Clinical Trials Registration NCT05294146

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofazimineMycobacterium Infections, NontuberculousAdultAgedFemaleHumansMaleMiddle AgedAnti-Bacterial AgentsNontuberculous Mycobacteria

Substanzen

Anti-Bacterial AgentsClofazimine

Autor:innen und Institutionen

  • Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pulmonary Diseases, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Department of Internal Medicine and Infectious Diseases, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Microbiology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Ralf Stemkens, Simon E Koele, Reinout van Crevel, Jakko van Ingen

Zitieren

APA

Stemkens, R., Lemson, A., Koele, S. E., Svensson, E. M., Te Brake, L. H. M., van Crevel, R., Boeree, M. J., Hoefsloot, W., van Ingen, J., & Aarnoutse, R. E. (2024). A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae309

Vancouver

Stemkens R, Lemson A, Koele SE, Svensson EM, Te Brake LHM, van Crevel R, et al. A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae309

BibTeX
@article{Stemkens2024,
  author = {Stemkens, Ralf and Lemson, Arthur and Koele, Simon E and Svensson, Elin M and Te Brake, Lindsey H M and van Crevel, Reinout and Boeree, Martin J and Hoefsloot, Wouter and van Ingen, Jakko and Aarnoutse, Rob E},
  title = {A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae309}
}
Kostenlos starten →